The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset

European Journal of Pharmacology

Volumn 635, Issue 1-3, 2010, Pages 109-116

  Tayarani Binazir, Kayhan A ^a   Jackson, Michael J ^a   Fisher, Ria ^a   Zoubiane, Ghada ^a   Rose, Sarah ^a   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Benserazide; Carbidopa; Dyskinesia; L DOPA; Motor disability; MPTP; Parkinson's disease; Primate

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE; CARBIDOPA; LEVODOPA; METHYLDOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CHOICE; DRUG EFFICACY; DRUG POTENTIATION; DYSKINESIA; FEMALE; LOCOMOTION; MALE; MARMOSET; MONOTHERAPY; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BENSERAZIDE; CALLITHRIX; CARBIDOPA; DOPA DECARBOXYLASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; LEVODOPA; MALE; METHYLDOPA; MOTOR ACTIVITY; MOVEMENT DISORDERS;

EID: 77952307194     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.03.006     Document Type: Article

References (30)

1. Admani A.K., Verma S., Cordingley G.J., Harris R.I. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients. Pharmatherapeutica 1985, 4:132-140.
2. Buck K., Ferger B. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats. Neurobiol. Dis. 2008, 29:210-220.
3. Campos-Romo A., Ojeda-Flores R., Moreno-Briseno P., Fernandez-Ruiz J. Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the HALLWAY task. J. Neurosci. Methods 2009, 177:361-368.
4. Cedarbaum J.M., Kutt H., Dhar A.K., Watkins S., McDowell F.H. Effect of supplemental carbidopa on bioavailability of L-dopa. Clin. Neuropharmacol. 1986, 9:153-159.
5. Close S.P., Marriott A.S., Pay S. Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in the marmoset. Br. J. Pharmacol. 1985, 85:320-322.
6. Da Prada P.M., Kettler R., Zurcher G., Schaffner R., Haefely W.E. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur. Neurol. 1987, 27(Suppl 1):9-20.
7. Fox S.H., Henry B., Hill M., Crossman A., Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 2002, 17:1180-1187.
8. Grange S., Holford N.H., Guentert T.W. A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats. Pharm. Res. 2001, 18:1174-1184.
9. Greenacre J.K., Coxon A., Petrie A., Reid J.L. Comparison of levodopa with carbidopa or benserazide in parkinsonism. Lancet 1976, 2:381-384.
10. Hadjiconstantinou M., Neff N.H. Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson's disease. CNS. Neurosci. Ther. 2008, 14:340-351.
11. Hagan R.M., Raxworthy M.J., Gulliver P.A. Benserazide and carbidopa as substrates of catechol-O-methyltransferase: new mechanism of action in Parkinson's disease. Biochem. Pharmacol. 1980, 29:3123-3126.
12. Hess S.M., Connamacher R.H., Ozaki M., Udenfriend S. The effects of alpha-methyl-DOPA and alpha-methyl-metatyrosine on the metabolism of norepinephrine and serotonin in vivo. J. Pharmacol. Exp. Ther. 1961, 134:129-138.
13. Iravani M.M., Tayarani-Binazir K., Chu W.B., Jackson M.J., Jenner P. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability. J. Pharmacol. Exp. Ther. 2006, 319:1225-1234.
14. Jackson M.J., Smith L.A., Al-Barghouthy G., Rose S., Jenner P. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Exp. Neurol. 2007, 204:162-170.
15. Jenner P., Marsden C.D. The actions of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in animals as a model of Parkinson's disease. Neural Trans. Suppl. 1986, 20:11-39.
16. Jonkers N., Sarre S., Ebinger G., Michotte Y. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J. Neural Transm. 2001, 108:559-570.
17. Kaakkola S., Teravainen H. Animal models of parkinsonism. Pharmacol. Toxicol. 1990, 67:95-100.
18. Korten J.J., Keyser A., Joosten E.M., Gabreels F.J. Madopar versus sinemet. A clinical study on their effectiveness. Eur. Neurol. 1975, 13:65-71.
19. Leppert P.S., Cortese M., Fix J.A. The effects of carbidopa dose and time and route of administration on systemic L-dopa levels in rats. Pharm. Res. 1988, 5:587-591.
20. Lieberman A., Goodgold A., Jonas S., Leibowitz M. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease. Neurology 1975, 25:911-916.
21. Marsden C.D., Parkes J.D., Rees J.E. A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet 1973, 2:1459-1462.
22. Nutt J.G., Woodward W.R., Anderson J.L. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann. Neurol. 1985, 18:537-543.
23. Pearce R.K., Jackson M., Smith L., Jenner P., Marsden C.D. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov. Disord. 1995, 10:731-740.
24. Pinder R.M., Brogden R.N., Sawyer P.R., Speight T.M., Avery G.S. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism. Drugs 1976, 11:329-377.
25. Quik M., Police S., Langston J.W., Di Monte D.A. Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey. Neuroscience 2002, 113:213-220.
26. Samadi P., Morissette M., Calon F., Hadj T.A., Dridi M., Belanger N., Meltzer L.T., Bedard P.J., Di P.T. Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys. Synapse 2008, 62:101-109.
27. Treseder S., Jackson M., Jenner P. The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates. Br. J. Pharmacol. 2000, 129(7):1355-1364.
28. Uspenskii A.E., Dabagov N.S., Skoldinov A.P. Pharmacology of several aromatic amino acid decarboxylase inhibitors. Bull. Eksp. Biol. Med. 1978, 86:444-447.
29. Van Zwieten P.A., Thoolen M.J., Timmermans P.B. The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine. Hypertension 1984, 6:II28-II33.
30. Yitey-Smith E., Varma D.R. Mechanism of the hypotensive action of methyldopa in normal and immunosympathectomized rats. Br. J. Pharmacol. 1970, 40:186-193.